The U.S. Food & Drug Administration declined to approve two China-tested cancer treatments on Monday, saying one of the companies – Hutchmed Ltd. – needs to test its drug for the U.S. population in a diverse multi-regional trial.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReutersFDAsign.jpg8001200Christiane Truelovehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngChristiane Truelove2022-05-02 09:48:272022-05-02 15:51:12U.S. FDA declines to approve two more China-tested drugs